CAS 118-00-3|Guanosine
Introduction：Basic information about CAS 118-00-3|Guanosine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Guanosine | ||
|---|---|---|---|
| CAS Number | 118-00-3 | Molecular Weight | 283.241 |
| Density | 2.3±0.1 g/cm3 | Boiling Point | 756.6±70.0 °C at 760 mmHg |
| Molecular Formula | C10H13N5O5 | Melting Point | 240ºC |
| MSDS | ChineseUSA | Flash Point | 411.4±35.7 °C |
| Symbol | GHS06 | Signal Word | Danger |
Names
| Name | guanosine |
|---|---|
| Synonym | More Synonyms |
Guanosine BiologicalActivity
| Description | Guanosine is a purine nucleoside comprising guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond. |
|---|---|
| Related Catalog | Natural Products >>OthersResearch Areas >>Others |
| Target | Human Endogenous Metabolite |
| In Vitro | Guanosine can be phosphorylated to become guanosine monophosphate (GMP), cyclic guanosine monophosphate (cGMP), guanosine diphosphate (GDP), and guanosine triphosphate (GTP). These forms play important roles in various biochemical processes such as synthesis of nucleic acids and proteins, photosynthesis, muscle contraction, and intracellular signal transduction (cGMP). |
Chemical & Physical Properties
| Density | 2.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 756.6±70.0 °C at 760 mmHg |
| Melting Point | 240ºC |
| Molecular Formula | C10H13N5O5 |
| Molecular Weight | 283.241 |
| Flash Point | 411.4±35.7 °C |
| Exact Mass | 283.091675 |
| PSA | 159.51000 |
| LogP | -3.27 |
| Vapour Pressure | 0.0±2.7 mmHg at 25°C |
| Index of Refraction | 1.955 |
| InChIKey | NYHBQMYGNKIUIF-UUOKFMHZSA-N |
| SMILES | Nc1nc2c(ncn2C2OC(CO)C(O)C2O)c(=O)[nH]1 |
| Storage condition | 2~8°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 180 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 1 gm/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 750 mg/kg
- SEX/DURATION :
- female 13 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- DOSE :
- 750 mg/kg
- SEX/DURATION :
- female 10 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Specific Developmental Abnormalities - musculoskeletal system
MUTATION DATA - TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Human Cells - not otherwise specified
- DOSE/DURATION :
- 1 mmol/L
- REFERENCE :
- JIDEAE Journal of Investigative Dermatology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1938- Volume(issue)/page/year: 65,52,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9994 No. of Facilities: 35 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 115 (estimated) No. of Female Employees: 64 (estimated)
- TYPE OF TEST :
- Mutation test systems - not otherwise specified
- TEST SYSTEM :
- Human Cells - not otherwise specified
- DOSE/DURATION :
- 1 mmol/L
- REFERENCE :
- JIDEAE Journal of Investigative Dermatology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1938- Volume(issue)/page/year: 65,52,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X9994 No. of Facilities: 35 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 115 (estimated) No. of Female Employees: 64 (estimated)
Safety Information
| Symbol | GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| Hazard Codes | T |
| Risk Phrases | R25 |
| Safety Phrases | S24/25 |
| RIDADR | UN2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | MF8750000 |
| Hazard Class | 6.1 |
| HS Code | 29349990 |
Customs
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles156
More Articles| Insights from reconstitution reactions of COPII vesicle formation using pure components and low mechanical perturbation. Biol. Chem. 395(7-8) , 801-12, (2014) As shape transformations of membranes are vital for intracellular trafficking, it is crucial to understand both the mechanics and the biochemistry of these processes. The interplay of these two factor... | |
| Hairpin assembly circuit-based fluorescence cooperative amplification strategy for enzyme-free and label-free detection of small molecule. Talanta 143 , 101-6, (2015) Here, we developed an enzyme-free, label-free, and sensitive fluorescence cooperative amplification strategy based on a hairpin assembly circuit which coupled catalytic hairpin assembly (CHA) with hyb... | |
| Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 350(3) , 589-604, (2014) Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for ser... |
Synonyms
| 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one |
| 2-Amino-9-(β-D-ribofuranosyl)-3,9-dihydro-6H-purin-6-on |
| MFCD00010182 |
| 2-amino-Inosine |
| Guanosine |
| 2-Amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-1,9-dihydro-6H-purin-6-one |
| 6H-Purin-6-one, 2-amino-1,9-dihydro-9-β-D-ribofuranosyl- |
| 9-(β-D-Ribofuranosyl)guanine |
| guanine riboside |
| Inosine,2-amino |
| 2-Amino-1,9-dihydro-9-β-D-ribofuranosyl-6H-purin-6-one |
| 2-Amino-9-(β-D-ribofuranosyl)-9H-purin-6-ol |
| EINECS 204-227-8 |
| 9-β-D-ribofuranosyl-Guanine |
| 2-Amino-9-(β-D-ribofuranosyl)-1,9-dihydro-6H-purin-6-on |
| vernine |
| 2H-purin-6-ol, 3,9-dihydro-2-imino-9-β-D-ribofuranosyl- |
| USAF CB-11 |
| Guanine-9-β-D-ribofuranoside |
| Guanosin |
| Guanosine Hydrate |
| Guanine, 9-β-D-ribofuranosyl- |
| 2-Amino-9-β-D-ribofuranosyl-9H-purine-6(1H)-one |
| 9-β-D-ribofuranosylguanine |
| 9H-purin-6-ol, 2-amino-9-β-D-ribofuranosyl- |
| 2-Amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one |
| Guanozin |
